
FDA Approves RAPIBLYK® (landiolol) for Pediatric Supraventricular Tachycardia Use
AOP Health US Secures FDA Approval for RAPIBLYK® (Landiolol) in Pediatric SVT Patients AOP Health US, LLC has announced a major regulatory milestone with the U.S. Food and Drug Administration (FDA) approving RAPIBLYK® (landiolol) for the treatment of pediatric patients…












